MediaAlpha enters its August 3 earnings report having underperformed a broadly stronger tape — and the insider register has been busy on the sell side throughout.
The most striking feature of the past two weeks is the cluster of insider selling at the top of the company. CEO and co-founder Steven Yi sold over 94,000 shares across July 16-17, raising roughly $1.36 million at prices around $14.20-14.39. Co-founder and Executive Director Eugene Nonko followed with six separate sales between July 20-22, offloading approximately 43,000 shares for around $606,000. CTO Kuanling Yeh also trimmed 13,000 shares in the same window. The 90-day net figure runs to approximately $8.3 million in gross proceeds across multiple insiders, with the selling concentrated precisely as the stock was trading near its recent highs. None of the trades are large enough individually to signal a dramatic shift in conviction — these carry low significance scores — but the breadth across three C-suite and founder-level insiders heading into a print is worth noting.
The lending market and short positioning tell a far more relaxed story. Short interest has been falling steadily, dropping nearly 8% on the week to 4.8% of free float — down from around 6.6% in early July. Borrow remains freely available, with availability at roughly 1,338% of short interest, meaning there are more than thirteen shares available to lend for every one currently borrowed. Cost to borrow is negligible at under 1%. This is not a stock where short sellers are pressing their case into the print; the positioning looks more like a gradual cover trade than any escalating bear thesis.
Options activity adds a minor wrinkle. The put/call ratio ticked up to 0.0104 on Tuesday, about 1.4 standard deviations above its 20-day average — still an extremely call-heavy book in absolute terms, but slightly less so than the recent norm. The 52-week PCR high is 0.45, so the market remains overwhelmingly positioned for upside. That call-skewed setup has been the prevailing tone all month, even as the stock gave back 2.8% on the week while close peers YELP, PINS, and GRND all gained 6-10%. QNST and EVER also lagged, falling around 1.8% and rising only 0.9% respectively, so the relative weakness is partly a sub-sector story — but MAX still trailed the group materially.
The analyst picture heading into the print is mixed by direction and stale by timing. The most recent move came from Keefe, Bruyette & Woods on July 8, raising its target from $15 to $17 while keeping an Outperform rating — the only bullish revision in recent months. Before that, TD Cowen trimmed its target to $11 in late June with a Hold, and the February earnings event prompted a sweep of cuts from Goldman Sachs, JPMorgan, RBC, and KBW, all maintaining their ratings but resetting to lower numbers. The consensus mean target of roughly $13.83 sits just above the current price of $13.79, offering little implied upside. Valuation has re-rated upward over the past month: the P/E has expanded by about 1.4 turns to 9.6x and price-to-book is up 0.2 turns to 2.1x — a modest but real re-rating driven by the stock's 16% gain over the past month. The analyst recommendation differential scores in the 98th percentile of the universe, suggesting the consensus skews bullish relative to peers, but EPS momentum scores are weak, ranking in just the 10th percentile on a 30-day basis.
The earnings history provides a clean base rate: the April 29 print saw the stock fall 15% the next day and lose a further 10% over the following week, while the May 5 event generated a flat-to-slightly-negative reaction. With the stock having recovered 16% in the month since those lows, what August 3 resolves is less about whether P&C vertical momentum is intact and more about whether the Health TV drag has stabilised and whether Q3 guidance can justify the recent re-rating.
See the live data behind this article on ORTEX.
Open MAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
